Shares of Endocyte, Inc. (NASDAQ:ECYT) have been assigned an average recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $13.50.

In other news, Director Fred A. Middleton purchased 10,000 shares of the company’s stock in a transaction on Tuesday, January 19th. The stock was purchased at an average price of $2.79 per share, with a total value of $27,900.00. Following the completion of the purchase, the director now directly owns 200,999 shares in the company, valued at approximately $560,787.21. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

A hedge fund recently bought a new stake in Endocyte stock. Simplex Trading purchased a new stake in Endocyte, Inc. (NASDAQ:ECYT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 29 shares of the biopharmaceutical company’s stock, valued at approximately $0.

Several equities research analysts recently issued reports on the company. Zacks Investment Research lowered Endocyte from a “buy” rating to a “hold” rating in a research note on Wednesday, January 6th. RBC Capital dropped their price objective on Endocyte from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, November 4th. Finally, Credit Suisse assumed coverage on Endocyte in a research note on Wednesday, January 20th. They set an “outperform” rating and a $11.00 price objective for the company.

Shares of Endocyte (NASDAQ:ECYT) opened at 3.47 on Thursday. The stock has a 50 day moving average price of $3.78 and a 200 day moving average price of $4.75. Endocyte has a 52 week low of $2.65 and a 52 week high of $6.76. The firm’s market cap is $145.65 million.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.03. The company earned $0.03 million during the quarter. During the same period in the prior year, the firm earned ($0.14) earnings per share. Endocyte’s revenue for the quarter was down 99.2% on a year-over-year basis. Equities analysts expect that Endocyte will post ($1.02) earnings per share for the current year.

Endocyte Inc. (NASDAQ:ECYT) is a biopharmaceutical company, developing therapies for the treatment of cancer and inflammatory diseases. The Company’s pipeline includes: Vintafolide (Vynfinit or EC145), which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells, but not on most normal cells; Folate-Tubulysin (EC1456), an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH); EC0652, a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169, an investigational, injectable, PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20), a folate-targeted molecular imaging agent; EC1669, a new approach to inflammation therapy, targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371, a folate-targeted, water-soluble form of rapamycin, and EC1788, a Folate-targeted SMDC.

12 Month Chart for NASDAQ:ECYT

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.